AHA 2022 Conference Coverage


 

AHA 2022: Sustained Blood Pressure Lowering Effect With the Dual Endothelin Receptor Antagonist Aprocitentan in Resistant Hypertension

1,537 views
November 16, 2022
2 Comments
Login to view comments. Click here to Login
Videos